Steven Blumenthal, MD
Cardiovascular Disease · Manhasset, NYNPI 1568441921
Payments from drug & device makers
Across 253 payments — averaging $48.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cardinal Health 110 LLC$7K
- Amgen$1K
- Boehringer Ingelheim$731
- Novartis$698
- Johnson & Johnson$692
- AstraZeneca$417
- plus $2K from 23 others
What the payments were for
- Consulting fees$6,50053%
- Food & beverage$5,85347%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cardinal Health 110 LLC | 6 | $6,500 |
| Amgen | 49 | $1,183 |
| Boehringer Ingelheim | 24 | $731 |
| Novartis | 45 | $698 |
| Johnson & Johnson | 26 | $692 |
| AstraZeneca | 25 | $417 |
| Merck | 13 | $320 |
| Regeneron Healthcare Solutions, Inc. | 8 | $215 |
| Medicomp Inc | 4 | $185 |
| Arbor Pharmaceuticals, Inc. | 8 | $174 |
| Pfizer | 7 | $153 |
| Abbott | 4 | $150 |
| Amarin Pharma, Inc. | 7 | $145 |
| Boston Scientific | 3 | $135 |
| Biotronik Inc. | 2 | $100 |
| Kowa Pharmaceuticals America, Inc. | 3 | $68 |
| Bardy Diagnostics, Inc. | 2 | $66 |
| Tanabe Pharma America, Inc. | 2 | $55 |
| Novo Nordisk | 2 | $51 |
| Lexicon Pharmaceuticals, Inc. | 2 | $45 |
| Cvrx, Inc. | 1 | $43 |
| Lundbeck LLC | 2 | $43 |
| Bridgebio Pharma, Inc. | 2 | $42 |
| Lilly USA, LLC | 1 | $30 |
| AbbVie | 1 | $25 |
| GSK | 1 | $24 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Heartflow, Inc. | 1 | $16 |
How this compares
$12,353 in reported general payments places this provider in the 80th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ShingrixVaricella-Zoster Ge/As01b/Pf | 743 | $138,916 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 481 | $123,559 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 164 | $46,180 |
| Repatha SureclickEvolocumab | 47 | $41,177 |
| EliquisApixaban | 33 | $36,300 |
| XareltoRivaroxaban | 19 | $23,567 |
| BrilintaTicagrelor | 20 | $14,528 |
| EntrestoSacubitril/Valsartan | 11 | $14,214 |
| JardianceEmpagliflozin | 15 | $11,660 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 178 | $10,602 |
| Metoprolol Succinate | 204 | $3,835 |
| Rosuvastatin Calcium | 174 | $3,280 |
| Dexlansoprazole DrDexlansoprazole | 13 | $2,748 |
| Nebivolol Hcl | 24 | $1,869 |
| Telmisartan | 34 | $1,406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKShingrix, Arexvy | $24 | $262,4751,224 claims |
| PfizerAbrysvo, Eliquis | $153 | $82,480197 claims |
| Johnson & JohnsonXarelto | $692 | $23,56719 claims |
| AstraZenecaBrilinta | $417 | $14,52820 claims |
| NovartisEntresto | $698 | $14,21411 claims |
| Boehringer IngelheimJardiance | $731 | $11,66015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in Manhasset
- Bruce RutkinManhasset$2.1M
- Loukas BoutisManhasset$782K
- Benjamin HirshManhasset$467K
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Vijay IyerAmherst$4.3M
- Gregg StoneNew York$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.